Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03684694 |
|
Recruitment Status :
Terminated
(Administrative decision)
First Posted : September 26, 2018
Last Update Posted : February 1, 2023
|
Sponsor:
ADC Therapeutics S.A.
Information provided by (Responsible Party):
ADC Therapeutics S.A.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | November 18, 2022 |
| Actual Study Completion Date : | November 18, 2022 |